Literature DB >> 21182497

The significance of anticardiolipin antibody and immunologic abnormality in livedoid vasculitis.

Su-ying Feng1, Pei-ying Jin, Chang-geng Shao.   

Abstract

OBJECTIVE: To evaluate the significance of anticardiolipin and immunologic abnormality in the livedoid vasculitis (LV).
METHODS: 30 patients with biopsy-proven LV and 30 normal controls involved in the study. Indirect immunofluorescence, immunoblot, and ELISA were used for detecting antinuclear antibody (ANA), circulating immune complex, immune globulin, anticardiophospholipin antibody (ACA), and anti-β(2) GP1.
RESULTS: ANA was positive in four patients with LV, and among them, two patients were diagnosed as Systemic Lupus Erythematosus (SLE) later. Addition to the two SLE patients, the level of ENA and immunoglobulin were normal in the rest of patients. Anticardiolipin antibodies were present in 13 (43.33%), and β(2) GP1 was present in nine (30%) of 30 patients. There were significant differences between LV and controls.
CONCLUSIONS: ACA is one of important pathogenesis of LV. Numerous heterogeneous coagulation abnormalities and thrombogenesis may involve the LV.
© 2011 The International Society of Dermatology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21182497     DOI: 10.1111/j.1365-4632.2010.04569.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  2 in total

1.  Livedoid vasculopathy as a marker of systemic disease: report of two cases.

Authors:  Raquel Sucupira Andrade Lima; Gustavo Ávila Maquiné; Carolina Talhari; Isabel Cristina Lima Encarnação; Antônio Pedro Mendes Schettini; Mônica Santos
Journal:  An Bras Dermatol       Date:  2014 Sep-Oct       Impact factor: 1.896

2.  Systemic lupus erythematosus with refractory ulcerated livedoid vasculopathy: Successful treatment with intravenous immunoglobulin and warfarin.

Authors:  Katsunobu Yoshioka; Chiharu Tateishi; Hiromi Kato; Ko-Ron Chen
Journal:  Clin Case Rep       Date:  2018-09-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.